WO2005098026A1 - カルボニックアンヒドラーゼi活性の測定法 - Google Patents
カルボニックアンヒドラーゼi活性の測定法 Download PDFInfo
- Publication number
- WO2005098026A1 WO2005098026A1 PCT/JP2005/006669 JP2005006669W WO2005098026A1 WO 2005098026 A1 WO2005098026 A1 WO 2005098026A1 JP 2005006669 W JP2005006669 W JP 2005006669W WO 2005098026 A1 WO2005098026 A1 WO 2005098026A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substrate
- cai
- caii
- inhibitor
- solution
- Prior art date
Links
- 108010033547 Carbonic Anhydrase I Proteins 0.000 title claims abstract description 172
- 102100025518 Carbonic anhydrase 1 Human genes 0.000 title claims abstract description 172
- 238000000034 method Methods 0.000 title claims abstract description 70
- 230000000694 effects Effects 0.000 title claims abstract description 55
- 239000000758 substrate Substances 0.000 claims abstract description 161
- 239000003112 inhibitor Substances 0.000 claims abstract description 121
- 108090000604 Hydrolases Proteins 0.000 claims abstract description 48
- 102000004157 Hydrolases Human genes 0.000 claims abstract description 48
- 230000009257 reactivity Effects 0.000 claims abstract description 28
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 20
- 102000004190 Enzymes Human genes 0.000 claims description 38
- 108090000790 Enzymes Proteins 0.000 claims description 38
- 238000005259 measurement Methods 0.000 claims description 24
- 150000002148 esters Chemical class 0.000 claims description 12
- 230000003301 hydrolyzing effect Effects 0.000 claims description 8
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 claims description 7
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 108090000371 Esterases Proteins 0.000 claims description 4
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 238000000691 measurement method Methods 0.000 claims description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 4
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 2
- 108010044467 Isoenzymes Proteins 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 157
- 238000002835 absorbance Methods 0.000 description 82
- 102000003846 Carbonic anhydrases Human genes 0.000 description 67
- 108090000209 Carbonic anhydrases Proteins 0.000 description 67
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 40
- 239000008213 purified water Substances 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 29
- 239000011701 zinc Substances 0.000 description 29
- 229910052725 zinc Inorganic materials 0.000 description 29
- 239000000523 sample Substances 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 26
- 210000003743 erythrocyte Anatomy 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000003153 chemical reaction reagent Substances 0.000 description 18
- 239000003623 enhancer Substances 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 239000006166 lysate Substances 0.000 description 15
- 229960000571 acetazolamide Drugs 0.000 description 13
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 13
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 12
- 239000007853 buffer solution Substances 0.000 description 10
- OREAFAJWWJHCOT-UHFFFAOYSA-N dimethylmalonic acid Chemical compound OC(=O)C(C)(C)C(O)=O OREAFAJWWJHCOT-UHFFFAOYSA-N 0.000 description 10
- 239000012488 sample solution Substances 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- -1 β-naphthyl ester Chemical class 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical compound COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 description 6
- 230000035484 reaction time Effects 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012954 diazonium Substances 0.000 description 2
- 150000001989 diazonium salts Chemical class 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229950000964 pepstatin Drugs 0.000 description 2
- 108010091212 pepstatin Proteins 0.000 description 2
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229940124036 Hydrolase inhibitor Drugs 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- 239000000987 azo dye Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 229960000722 brinzolamide Drugs 0.000 description 1
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
- 229960003933 dorzolamide Drugs 0.000 description 1
- 239000004093 hydrolase inhibitor Substances 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- 229960004083 methazolamide Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
Definitions
- the present invention relates to a method and a kit for measuring the activity of carbonic anhydrase I (CAI; sometimes referred to as carbonic anhydrase B).
- CAI carbonic anhydrase I
- CAII Carbonic anhydrase
- erythrocytes erythrocytes
- CAII Carbonic anhydrase
- isozyme has been suggested to be applied to clinical diagnosis of hyperthyroidism / hypothyroidism different from the total amount of CA !, Non-Patent Document 1.
- CA has a hydrolase activity in addition to carbonic anhydrase activity, and by utilizing this hydrolase activity, the CA isozyme activity can be easily determined by, for example, a spectroscopic method. It can be measured (Non-Patent Document 2).
- Non-Patent Document 2 Non-Patent Document 2
- a large amount of hydrolases other than CA is present, and under conditions where degradation of the added substrate by these enzymes cannot be ignored, for example, the added substrate may be rapidly degraded. Under the conditions, it was considered impossible to specifically measure the hydrolase activity of the CA isozyme.
- Non-Patent Document 3 a method of measuring a hydrolase activity before and after immunoadsorption using an antiserum against CAI to specifically measure CAI activity.
- Non-patent literature l Tohoku J. Exp.Med., 1996, 178, 345-356
- Non-Patent Document 2 The Journal of Biological Chemistry, 1967; 242 (18): 422
- Non-patent document 3 Clinica Chimica Acta, 60 (1975), 347-353
- Non-patent document 4 The Journal of Biological Chemistry, 1966; 241 (10): 513
- the present invention provides a method for measuring the activity of a hydrolytic enzyme of carbonic anhydrase I (CAI) in a sample, wherein the substrate used for the measurement or the combination of the substrate and the inhibitor is as follows:
- the present invention provides a method for measuring CAI activity, which comprises using any one of A) to (E).
- Inhibitors Inhibitors that inhibit hydrolases other than CA
- CA inhibitor that inhibits both CAI and CAII
- CA inhibitors that inhibit CAI more strongly than CAII
- CA inhibitors that inhibit CAI more strongly than CAII The present invention also provides a kit for measuring the activity of a CAI hydrolase in a sample, comprising a substrate, a substrate and an inhibitor, or a combination of a substrate, an inhibitor and an enhancer used in the measurement. Accordingly, the present invention provides a kit for measuring CAI activity, characterized by containing any of the above (A) to (E).
- the use of a specific substrate, a specific substrate and an inhibitor, or a combination of a specific substrate, an inhibitor and an enhancer enables the activity of CAI hydrolase in a sample to be measured. Can be measured specifically, selectively or substantially, and the operation is simple. As in clinical specimens, a large amount of hydrolytic enzymes other than CA exist, and the degradation of the added substrate by these enzymes cannot be ignored. It is a practical method for measuring CAI activity because it can be applied under conditions that cause degradation. Among them, the method using the combination of the specific substrate, the inhibitor and the enhancer described in (B) above can eliminate the influence of hydrolases other than CA, and can carry out the CAI hydrolase in one measurement. This is a very useful method because the activity can be measured specifically.
- the sample is not particularly limited as long as it is a sample containing a red blood cell component, but is preferably a red blood cell lysate. Further, even if blood components other than red blood cells are mixed, they can be used as a sample.
- the present invention relates to a method for measuring the activity of a CAI hydrolase in a sample, which comprises a substrate, a substrate and an inhibitor, or a combination of a substrate, an inhibitor and an enhancer used in the measurement.
- a measurement method characterized by using any of the following (A) to (E).
- Inhibitors Inhibitors that inhibit hydrolases other than CA
- Inhibitor CA inhibitor that inhibits both CAI and CAII (D)
- Substrate Substrate that reacts with both CAI and CAII
- CA inhibitors that inhibit CAI more strongly than CAII
- CA inhibitors that inhibit CAI more strongly than CAII
- any one of the above (A) and (B) is used as a substrate, a substrate and an inhibitor, or a combination of a substrate, an inhibitor and an enhancer,
- the hydrolase activity in the sample, specifically the esterase activity is measured under two conditions, in the presence and absence of the CA inhibitor, and the difference is determined by the CAI hydrolase activity
- the above two methods are included.
- the term "substrate having higher reactivity to CAI than CAII” means that the reaction amount per CAI enzyme protein (substrate change amount) depends on the substrate concentration, reaction time, etc. Substrate that is more than twice as large.
- esters such as 2-hydroxy-5-toluene toluenesulfonic acid sultone, o-trophenyl ester, p-trophenyl thioester, ⁇ -naphthyl ester and the like are preferable, and o-trophenyl ester is particularly preferred.
- These esters are preferably fatty acid esters, and more preferably fatty acid esters having 1 to 6 carbon atoms, and specifically, o-trophenyl acetate.
- substrate that reacts with both CAI and CAII means that the reaction amount per CAI enzyme protein (substrate change amount) is twice as large as the CAII reaction amount, depending on the substrate concentration, reaction time, etc. Substrate is less than.
- examples thereof include esters different from the above, such as p-trophenyl ester and a-naphthyl ester, and P-trophenyl ester is particularly preferred. These esters are preferably fatty acid esters, more preferably fatty acid esters having 1 to 6 carbon atoms, and more preferably P-trophenyl acetate.
- inhibitor that inhibits a hydrolase other than CA refers to an enzyme of a hydrolase other than CA by setting a substrate concentration, an inhibitor concentration, a reaction time, and the like.
- protease inhibitor cocktails catalog. No. P2714 and P83 40 (Sigma)
- AEBSF 4- (2-aminoethyl) benzenesulfur fluoride
- PMSF a-phenylmethanesulfur fluoride
- a drug that enhances the inhibitory action of the inhibitor means an agent that does not have an inhibitory action by itself but enhances the inhibitory action of the above-mentioned hydrolase inhibitor.
- the enhancer include aldehydes such as formaldehyde, acetoaldehyde, and dataraldehyde.
- a "CA inhibitor that more strongly inhibits CAI than CAII” refers to a CAII inhibitory effect on the amount of CAI reaction change per enzyme protein amount, depending on the settings of substrate concentration, inhibitor concentration, and reaction time. Means a CA inhibitor that is more than twice the inhibitory effect on the amount of reaction.
- imidazole, anions (CNS-, CNO ", CN", ⁇ , etc.) and the like can be mentioned.
- CA inhibitor that inhibits both CAI and CAII refers to the reaction per CAI enzyme protein compared to the case where no inhibitor is used, by setting the substrate concentration, inhibitor concentration, and reaction time.
- a CA inhibitor whose inhibitory effect on the amount (substrate change) is less than twice the inhibitory effect on the reaction amount of CAII.
- examples thereof include amides (eg, dorzolamide, brinzolamide, acetazolamide, methazolamide, etc.) and rubamoyl phosphate, particularly preferably acetazonolamide.
- Substrate nitrophenylesters, especially substrates that are more reactive to CAI than CAII. 12 trowel acetate
- Inhibitors As inhibitors that inhibit hydrolases other than CA, protease inhibitor cocktail, AEBSF or pepstatin, especially AEBSF
- Enhancers Agents that enhance the action of inhibitors include aldehydes, especially formaldehyde,
- Inhibitors Inhibits both CAI and CAII As inhibitors of CA, amides,
- Inhibitors Inhibits CAI more strongly than CAII.
- Inhibitors Inhibits CAI more strongly than CAII.
- the amount of reaction per amount of enzyme protein can be determined by a conventional method for measuring the reaction rate of an enzyme, such as substrate concentration, enzyme concentration, inhibitor concentration, reaction temperature, reaction PH and reaction time. It can be measured by setting constant conditions.
- a substrate that is degraded by a hydrolase an inhibitor that inhibits a hydrolase other than CA, and an action of inhibiting the hydrolase activity of the inhibitor.
- Enhancers that enhance the activity of CA or CA inhibitors that do not inhibit hydrolases other than CA and have the above-mentioned properties can be used as the substrate, inhibitor, and enhancer of the present invention.
- the measurement of the hydrolase activity in the sample is not particularly limited, and a conventional method suitable for the substrate used may be employed. Specifically, a method using a spectrophotometer, a method for producing diazonium salts and azo dyes and quantifying them, a pH-stat method, and the like can be adopted (for example, see Masai Kanai, “Clinical Inspection Methods”). (Kanehara Publishing Co., Ltd., published on December 10, 1996, 30th edition, pages 312-315, edited by The Chemical Society of Japan, Biochemical Data Book II, pages 6-269)
- the present invention can provide a kit for measuring a CAI hydrolase activity, which contains any one of the combinations of (A) to (E) described above.
- a kit may include the following reagents.
- sample diluents to which inhibitors and enhancers have been added in advance.
- it may be a substrate solution.
- an enhancer may be further attached.
- select reagents according to the measurement method from reagents such as diazonium salt reagents, reagents for stopping the reaction, standard enzyme reagents, and reagents for sample pretreatment. Attach the kit of the invention.
- the substrate used was o--trophenyl acetate, which is more reactive to CAI than CAII, and no inhibitor was used.
- Table 1 shows the measurement results. As is evident from Table 1, it was revealed that CAI can be substantially measured even with the substrate o --- trophenyl acetate alone having a higher reactivity to CAI than CAII.
- Human erythrocyte lysate was used as a sample.
- o-ditrophenyl acetate which is more reactive to CAI than CAII, as a substrate, and 4- (2-aminoethyl) benzenesulfonate as an inhibitor that inhibits hydrolases other than CA -Fluoride (AEBSF) and formaldehyde as its enhancer.
- AEBSF CA -Fluoride
- Table 2 shows the measurement results. As is evident from Table 2, CAI is more specific when the substrate is more reactive to CAI than CAII. It became clear that it could be measured.
- Human erythrocyte lysate was used as a sample.
- O--Trophenyl acetate which is more reactive to CAI than CAII, is used as a substrate, and 4- (2-aminoethyl) benzenesulfonate is used as an inhibitor to inhibit hydrolases other than CA.
- -Fluoride (AEBSF) and formaldehyde as its enhancer.
- the zinc concentration on the horizontal axis indicates the zinc concentration (mgZD) in the sample determined by the atomic absorption method because CAI is a zinc enzyme that binds to 80% or more of zinc in erythrocytes.
- the use of an inhibitor that inhibits a hydrolase other than CA and an enhancer thereof can suppress the mixed hydrolase activity, and the CAI concentration and the zinc concentration are reduced. It shows a good correlation and y-intercept (correlation coefficient: 0.9577, y-intercept: 2.00898), and the method of the present invention shows that a large amount of hydrolytic enzymes other than CA such as clinical specimens is present. It was confirmed that the decomposition of the added substrate was a practical method for measuring CA I that could be applied even under non-negligible conditions.
- O-Ditrophenyl acetate which is more reactive to CAI than CAII
- acetazolamide which inhibits both CAI and CAII
- p-nit p--trophenol-acetate
- Acetazolamide was used as a CA inhibitor in the same manner as described above.
- CA-specific absorbance change [ ⁇ A1— ⁇ A3] — [ ⁇ A2— ⁇ A4]
- Table 3 shows the measurement results. As is evident from Table 3, in the combination of p--trofuhl-acetate and acetazolamide, the reactivity of p--trofuhl-acetate as a substrate is less than twice that of CAI and CAII. O- -Trofuhl-acetate is not specific to CAI and reacts to both CAI and CAII, so we cannot measure CAI specifically. O- -Trofuhl-acetate and acetazolamide In a combination of It was evident that the reactivity of o--trophyl-acetate as a substrate was more than twice the difference between CAI and CAII, so that it was possible to specifically measure CAI.
- Human erythrocyte lysate was used as a sample.
- O--Trophenyl acetate was used as a substrate and acetazolamide was used in combination as an inhibitor.
- CA-specific absorbance change [ ⁇ A1— ⁇ A3] — [ ⁇ A2— ⁇ A4]
- P--Trophenyl acetate which reacts to both CAI and CAII, is used as a substrate. Used together.
- CA-specific absorbance change [ ⁇ A1— ⁇ A3] — [ ⁇ A2— ⁇ A4]
- Table 4 shows the measurement results. As is evident from Table 4, even if the substrate P --- trophyl-acetate reacts with both CAI and CAII, CAI can be specifically inhibited when combined with iodine ion, which inhibits CAI more strongly than CAII, as a CA inhibitor. It became clear that we could measure
- Human erythrocyte lysate was used as a sample.
- CAI-specific absorbance change [ ⁇ A1— ⁇ A3] — [ ⁇ A2— ⁇ A4]
- Fig. 4 shows the results.
- CAI concentration on the vertical axis 20 8! 111 using human JICA 1 solution instead of the sample solution the result in terms of mg of CAI of human erythrocyte lysate based on hemoglobin it to further (Hb) and expressed as mgZgHb.
- the zinc concentration on the horizontal axis indicates the zinc concentration (mgZD) in the sample determined by the atomic absorption method because CAI is a zinc enzyme that binds to 80% or more of zinc in erythrocytes.
- O--Trofuryl acetate (o- nitrophenyl acetate), which is more reactive to CAI than CAII, is used as a substrate. Used together.
- CA-specific absorbance change [ ⁇ A1— ⁇ A3] — [ ⁇ A2— ⁇ A4]
- Table 5 shows the measurement results. As is evident from Table 5, the substrate o- -trophenyl acetate, which is more reactive to CAI than CAII, inhibits CAI more strongly than CAII as a CA inhibitor It became clear that CAI can be measured specifically when combined with iodine ions [Table 5]
- Human erythrocyte lysate was used as a sample.
- O--Trophenyl acetate was used as a substrate, and iodine ion was used in combination as a CA inhibitor.
- ⁇ 1 change in absorbance when using (1) solution, (2) control solution, and (3) solution
- CAI-specific absorbance change [ ⁇ A1— ⁇ A3] — [ ⁇ A2— ⁇ A4]
- Fig. 5 shows the results.
- CAI concentration on the vertical axis 20 8! 111 using human JICA 1 solution instead of the sample solution the result in terms of mg of CAI of human erythrocyte lysate based on hemoglobin it to further (Hb) and expressed as mgZgHb.
- the zinc concentration on the horizontal axis indicates the zinc concentration (mgZD) in the sample determined by the atomic absorption method because CAI is a zinc enzyme that binds to 80% or more of zinc in erythrocytes.
- the method of the present invention is a condition in which a large amount of hydrolytic enzymes other than CA such as clinical specimens are present, and degradation of the added substrate by those enzymes cannot be ignored. It was confirmed that it was a practical method for specific CAI measurement that could be applied below.
- FIG. 1 shows the measurement results in Example 2, in which the horizontal axis represents the zinc concentration by the atomic absorption method as a control and the vertical axis represents the CAI concentration by the present method. This is a plot of the measurement results.
- Fig. 2 shows the measurement results in Example 4, where the horizontal axis represents the zinc concentration by the atomic absorption method as a control and the vertical axis represents the CAI concentration by the present method. Is plotted.
- Fig. 3 shows the measurement results in Example 6, in which the horizontal axis represents the zinc concentration by the atomic absorption method as a control and the vertical axis represents the CAI concentration by the present method. Is plotted.
- Fig. 4 shows the measurement results in Example 8, in which the horizontal axis represents the zinc concentration by the atomic absorption method as a control and the vertical axis represents the CAI concentration by the present method. Plot It was done.
- Fig. 5 shows the measurement results in Example 10, where the horizontal axis represents the zinc concentration by the atomic absorption method as a control and the vertical axis represents the CAI concentration by the present method. It is the plots.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/547,249 US20070196885A1 (en) | 2004-04-05 | 2005-04-05 | Method of determining carbonic anhydrase i activity |
EP05728780A EP1734132A4 (en) | 2004-04-05 | 2005-04-05 | METHOD FOR DETERMINING CARBONIC ANHYDRASE ACTIVITY I |
JP2006512089A JP4820289B2 (ja) | 2004-04-05 | 2005-04-05 | カルボニックアンヒドラーゼi活性の測定法 |
US12/769,181 US20100209953A1 (en) | 2004-04-05 | 2010-04-28 | Method of determining carbonic anhydrase i activity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-111051 | 2004-04-05 | ||
JP2004111051 | 2004-04-05 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/769,181 Division US20100209953A1 (en) | 2004-04-05 | 2010-04-28 | Method of determining carbonic anhydrase i activity |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005098026A1 true WO2005098026A1 (ja) | 2005-10-20 |
Family
ID=35125085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/006669 WO2005098026A1 (ja) | 2004-04-05 | 2005-04-05 | カルボニックアンヒドラーゼi活性の測定法 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20070196885A1 (ja) |
EP (1) | EP1734132A4 (ja) |
JP (1) | JP4820289B2 (ja) |
WO (1) | WO2005098026A1 (ja) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6821997B1 (en) * | 2000-10-16 | 2004-11-23 | Victorio C. Rodriguez | Therapeutic and prophylactic treatment of aging and disorders of aging in humans |
-
2005
- 2005-04-05 JP JP2006512089A patent/JP4820289B2/ja not_active Expired - Fee Related
- 2005-04-05 US US11/547,249 patent/US20070196885A1/en not_active Abandoned
- 2005-04-05 WO PCT/JP2005/006669 patent/WO2005098026A1/ja not_active Application Discontinuation
- 2005-04-05 EP EP05728780A patent/EP1734132A4/en not_active Withdrawn
-
2010
- 2010-04-28 US US12/769,181 patent/US20100209953A1/en not_active Abandoned
Non-Patent Citations (3)
Title |
---|
KONDO T. ET AL: "Estimations of active and inactive carbonic anhydrase isozyme B in human red cells", CLINICA CHIMICA ACTA, vol. 60, 1975, pages 347 - 353, XP002994538 * |
See also references of EP1734132A4 * |
TOHOKU J.: "Effects of Thyroid Hormone on Erythrocyte Carbonic Anhydrase-I and Zinc Concentrations In Vivo and In Vitro: Clinical Usefulness of Carbonic Anhydrase-I and Zinc Concentrations in Erythrocytes.", J. EXP. MED., vol. 178, 1996, pages 345 - 356, XP008059737 * |
Also Published As
Publication number | Publication date |
---|---|
US20070196885A1 (en) | 2007-08-23 |
JP4820289B2 (ja) | 2011-11-24 |
EP1734132A4 (en) | 2009-08-26 |
US20100209953A1 (en) | 2010-08-19 |
JPWO2005098026A1 (ja) | 2008-02-28 |
EP1734132A1 (en) | 2006-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2610074B2 (ja) | 液体中のイオンを測定する方法及びそのための組成物 | |
US4743561A (en) | Luminescent assay with a reagent to alter transmitive properties of assay solution | |
JPH0354304B2 (ja) | ||
JP2796462B2 (ja) | エタノール分析用組成物 | |
JPS6336759B2 (ja) | ||
US5420008A (en) | Assay method and assay reagent for serum iron or unsaturated iron binding capacity | |
JP5017614B2 (ja) | 試料中の測定対象物質の測定方法及び測定試薬、非特異的発色を抑制する方法、並びに非特異的発色抑制剤 | |
WO2005098026A1 (ja) | カルボニックアンヒドラーゼi活性の測定法 | |
JP4691627B2 (ja) | 非特異的発色の抑制方法 | |
JP5216968B2 (ja) | テトラゾリウム化合物を色原体として用いる試料中の測定対象物質の測定方法及び測定試薬、非特異的発色を抑制する方法、並びに非特異的発色抑制剤 | |
WO2006030866A1 (ja) | 尿酸の定量方法 | |
US5888828A (en) | Kit for measuring urea nitrogen | |
JP3164165B2 (ja) | カルシウムの定量方法 | |
JP2006325547A (ja) | フルクトシルペプチドオキシダ−ゼの安定化方法 | |
JP3428073B2 (ja) | 1,5−アンヒドログルシトールの定量法 | |
JP3415873B2 (ja) | 1,5−アンヒドログルシトールの定量法 | |
JPH04271799A (ja) | クレアチニンを酵素により測定する方法および試薬 | |
AU662510B2 (en) | Determination of ions in fluids | |
JP3287879B2 (ja) | 1,5−アンヒドログルシトールの定量法 | |
JP2000166595A (ja) | 抱合型ビリルビン測定用試薬 | |
JPH02255098A (ja) | グアニジノ酢酸の定量法 | |
JPH05111395A (ja) | 生体試料中の成分の微量分析方法 | |
JPH06237794A (ja) | 1,5−アンヒドログルシトールの定量法 | |
RU2081411C1 (ru) | Композиция для определения ионов натрия (варианты) | |
JP2024017996A (ja) | 試料中の検査対象物質の定量用試薬キットおよび定量方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006512089 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005728780 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11547249 Country of ref document: US Ref document number: 2007196885 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005728780 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11547249 Country of ref document: US |